BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...cell therapy company SQZ Biotechnologies Co. as CBO. He was VP of corporate development at MeiraGTx...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

...is SVP, head of global market access and pricing at Daiichi Sankyo Co. Ltd. (Tokyo:4568). MeiraGTx...
...“Kira: Depleting Activated Dendritic Cells” ). Robin Sawka, BioCentury Staff Alexion Pharmaceuticals Inc. WuXi Biologics Inc. Dicerna Pharmaceuticals Inc. Valneva SE MeiraGTx...
BioCentury | Dec 4, 2019
Company News

Audentes takeout signals pharma's continued interest in gene therapy manufacturing

...therapeutics, several companies including Audentes Therapeutics Inc. (NASDAQ:BOLD), uniQure N.V. (NASDAQ:QURE), RegenxBio Inc. (NASDAQ:RGNX) and MeiraGTx...
...gainers were uniQure, which rose $9.14 (17%) to $63.92; RegenxBio, which gained $3.82 to $44.50; MeiraGTx...
...gene therapy but have yet to bring manufacturing in-house. JNJ's Janssen unit is collaborating with MeiraGTx...
BioCentury | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

...notes due 2024. The company markets PARP inhibitor Rubraca rucaparib. MeiraGTx raises $75.2M in follow-on MeiraGTx...
...and Hongjiang Li, Staff Writer Beijing Biocytogen Co. Ltd. Clovis Oncology Inc. Dynavax Technologies Corp. Ironwood Pharmaceuticals Inc. Kangpu Biopharmaceuticals Ltd. MeiraGTx...
BioCentury | Apr 22, 2019
Company News

Management tracks: MeiraGTx, Retrophin, Aduro

...on April 16, a little over six months after she joined the gene therapy company. MeiraGTx...
...Transmembrane protein 173; TNFSF13 (APRIL) - Tumor necrosis factor ligand superfamily member 13 BioCentury Staff Aduro Biotech Epic Sciences MeiraGTx Neurelis Prime...
BioCentury | Mar 1, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

...vectorized antibodies. Other companies have gene therapies in development for PD, but none target α-synuclein. MeiraGTx...
BioCentury | Mar 1, 2019
Financial News

After J&J retinal dea, MeiraGTx raises $80M for partnered programs

...which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC Inc. MeiraGTx...
...and AAV-CNGA3 (see "J&J, MeiraGTx Partner on Gene Therapies for Rare Retinal Diseases" ). A MeiraGTx...
...participated in the placement. MeiraGTx Holdings plc (NASDAQ:MGTX), New York, N.Y. Elizabeth S. Eaton AAV-AQP1 (A00X) AAV-GAD (NLX-P101, NLX-XI) MeiraGTx...
BioCentury | Feb 27, 2019
Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

...which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC Inc. MeiraGTx...
...million shares at $13.80, a 4% premium to its close Tuesday of $13.27. Last month, MeiraGTx...
...and AAV-CNGA3 (see "J&J, MeiraGTx Partner on Gene Therapies for Rare Retinal Diseases" ). A MeiraGTx...
BioCentury | Feb 23, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

...vectorized antibodies. Other companies have gene therapies in development for PD, but none target α-synuclein. MeiraGTx...
BioCentury | Jan 31, 2019
Company News

J&J, MeiraGTx partner on gene therapies for rare retinal diseases

...a worldwide licensing deal with MeiraGTx Holdings plc (NASDAQ:MGTX) for rare inherited retinal disease therapies. MeiraGTx...
...jointly develop MeiraGTx's AAV manufacturing platform and share those costs. The deal does not include MeiraGTx’s...
...editing, including one with MeiraGTx. In October 2018, the companies announced a research partnership where MeiraGTx...
Items per page:
1 - 10 of 20
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...cell therapy company SQZ Biotechnologies Co. as CBO. He was VP of corporate development at MeiraGTx...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

...is SVP, head of global market access and pricing at Daiichi Sankyo Co. Ltd. (Tokyo:4568). MeiraGTx...
...“Kira: Depleting Activated Dendritic Cells” ). Robin Sawka, BioCentury Staff Alexion Pharmaceuticals Inc. WuXi Biologics Inc. Dicerna Pharmaceuticals Inc. Valneva SE MeiraGTx...
BioCentury | Dec 4, 2019
Company News

Audentes takeout signals pharma's continued interest in gene therapy manufacturing

...therapeutics, several companies including Audentes Therapeutics Inc. (NASDAQ:BOLD), uniQure N.V. (NASDAQ:QURE), RegenxBio Inc. (NASDAQ:RGNX) and MeiraGTx...
...gainers were uniQure, which rose $9.14 (17%) to $63.92; RegenxBio, which gained $3.82 to $44.50; MeiraGTx...
...gene therapy but have yet to bring manufacturing in-house. JNJ's Janssen unit is collaborating with MeiraGTx...
BioCentury | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

...notes due 2024. The company markets PARP inhibitor Rubraca rucaparib. MeiraGTx raises $75.2M in follow-on MeiraGTx...
...and Hongjiang Li, Staff Writer Beijing Biocytogen Co. Ltd. Clovis Oncology Inc. Dynavax Technologies Corp. Ironwood Pharmaceuticals Inc. Kangpu Biopharmaceuticals Ltd. MeiraGTx...
BioCentury | Apr 22, 2019
Company News

Management tracks: MeiraGTx, Retrophin, Aduro

...on April 16, a little over six months after she joined the gene therapy company. MeiraGTx...
...Transmembrane protein 173; TNFSF13 (APRIL) - Tumor necrosis factor ligand superfamily member 13 BioCentury Staff Aduro Biotech Epic Sciences MeiraGTx Neurelis Prime...
BioCentury | Mar 1, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

...vectorized antibodies. Other companies have gene therapies in development for PD, but none target α-synuclein. MeiraGTx...
BioCentury | Mar 1, 2019
Financial News

After J&J retinal dea, MeiraGTx raises $80M for partnered programs

...which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC Inc. MeiraGTx...
...and AAV-CNGA3 (see "J&J, MeiraGTx Partner on Gene Therapies for Rare Retinal Diseases" ). A MeiraGTx...
...participated in the placement. MeiraGTx Holdings plc (NASDAQ:MGTX), New York, N.Y. Elizabeth S. Eaton AAV-AQP1 (A00X) AAV-GAD (NLX-P101, NLX-XI) MeiraGTx...
BioCentury | Feb 27, 2019
Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

...which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC Inc. MeiraGTx...
...million shares at $13.80, a 4% premium to its close Tuesday of $13.27. Last month, MeiraGTx...
...and AAV-CNGA3 (see "J&J, MeiraGTx Partner on Gene Therapies for Rare Retinal Diseases" ). A MeiraGTx...
BioCentury | Feb 23, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

...vectorized antibodies. Other companies have gene therapies in development for PD, but none target α-synuclein. MeiraGTx...
BioCentury | Jan 31, 2019
Company News

J&J, MeiraGTx partner on gene therapies for rare retinal diseases

...a worldwide licensing deal with MeiraGTx Holdings plc (NASDAQ:MGTX) for rare inherited retinal disease therapies. MeiraGTx...
...jointly develop MeiraGTx's AAV manufacturing platform and share those costs. The deal does not include MeiraGTx’s...
...editing, including one with MeiraGTx. In October 2018, the companies announced a research partnership where MeiraGTx...
Items per page:
1 - 10 of 20